nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftaroline fosamil—Phlebitis—Carboplatin—esophageal cancer	0.08	0.08	CcSEcCtD
Ceftaroline fosamil—Swelling face—Capecitabine—esophageal cancer	0.0431	0.0431	CcSEcCtD
Ceftaroline fosamil—Pain—Carboplatin—esophageal cancer	0.029	0.029	CcSEcCtD
Ceftaroline fosamil—Hyperkalaemia—Cisplatin—esophageal cancer	0.0274	0.0274	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Carboplatin—esophageal cancer	0.0268	0.0268	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Cisplatin—esophageal cancer	0.0235	0.0235	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Cisplatin—esophageal cancer	0.0184	0.0184	CcSEcCtD
Ceftaroline fosamil—Phlebitis—Capecitabine—esophageal cancer	0.0173	0.0173	CcSEcCtD
Ceftaroline fosamil—Renal failure—Cisplatin—esophageal cancer	0.0153	0.0153	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0147	0.0147	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Cisplatin—esophageal cancer	0.0142	0.0142	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Cisplatin—esophageal cancer	0.0138	0.0138	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Cisplatin—esophageal cancer	0.0137	0.0137	CcSEcCtD
Ceftaroline fosamil—Hypokalaemia—Capecitabine—esophageal cancer	0.0136	0.0136	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Cisplatin—esophageal cancer	0.0126	0.0126	CcSEcCtD
Ceftaroline fosamil—Erythema—Cisplatin—esophageal cancer	0.0122	0.0122	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Cisplatin—esophageal cancer	0.0122	0.0122	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Capecitabine—esophageal cancer	0.012	0.012	CcSEcCtD
Ceftaroline fosamil—Hyperglycaemia—Capecitabine—esophageal cancer	0.0116	0.0116	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Capecitabine—esophageal cancer	0.0115	0.0115	CcSEcCtD
Ceftaroline fosamil—Infestation—Capecitabine—esophageal cancer	0.0115	0.0115	CcSEcCtD
Ceftaroline fosamil—Renal failure—Capecitabine—esophageal cancer	0.0113	0.0113	CcSEcCtD
Ceftaroline fosamil—Anaemia—Cisplatin—esophageal cancer	0.0113	0.0113	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Capecitabine—esophageal cancer	0.0109	0.0109	CcSEcCtD
Ceftaroline fosamil—Convulsion—Cisplatin—esophageal cancer	0.0105	0.0105	CcSEcCtD
Ceftaroline fosamil—Bradycardia—Capecitabine—esophageal cancer	0.0105	0.0105	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Capecitabine—esophageal cancer	0.0103	0.0103	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0103	0.0103	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Capecitabine—esophageal cancer	0.0102	0.0102	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Capecitabine—esophageal cancer	0.0101	0.0101	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Cisplatin—esophageal cancer	0.00993	0.00993	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Cisplatin—esophageal cancer	0.00974	0.00974	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Cisplatin—esophageal cancer	0.00973	0.00973	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Cisplatin—esophageal cancer	0.00965	0.00965	CcSEcCtD
Ceftaroline fosamil—Eosinophilia—Methotrexate—esophageal cancer	0.00949	0.00949	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Capecitabine—esophageal cancer	0.00935	0.00935	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Capecitabine—esophageal cancer	0.00931	0.00931	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Capecitabine—esophageal cancer	0.00897	0.00897	CcSEcCtD
Ceftaroline fosamil—Erythema—Capecitabine—esophageal cancer	0.00897	0.00897	CcSEcCtD
Ceftaroline fosamil—Neutropenia—Methotrexate—esophageal cancer	0.00896	0.00896	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00858	0.00858	CcSEcCtD
Ceftaroline fosamil—Infestation NOS—Methotrexate—esophageal cancer	0.00855	0.00855	CcSEcCtD
Ceftaroline fosamil—Infestation—Methotrexate—esophageal cancer	0.00855	0.00855	CcSEcCtD
Ceftaroline fosamil—Pain—Cisplatin—esophageal cancer	0.0085	0.0085	CcSEcCtD
Ceftaroline fosamil—Renal failure—Methotrexate—esophageal cancer	0.0084	0.0084	CcSEcCtD
Ceftaroline fosamil—Anaemia—Capecitabine—esophageal cancer	0.00829	0.00829	CcSEcCtD
Ceftaroline fosamil—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00808	0.00808	CcSEcCtD
Ceftaroline fosamil—Palpitations—Capecitabine—esophageal cancer	0.00793	0.00793	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Cisplatin—esophageal cancer	0.00785	0.00785	CcSEcCtD
Ceftaroline fosamil—Hepatitis—Methotrexate—esophageal cancer	0.00767	0.00767	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00759	0.00759	CcSEcCtD
Ceftaroline fosamil—Urinary tract disorder—Methotrexate—esophageal cancer	0.00758	0.00758	CcSEcCtD
Ceftaroline fosamil—Urethral disorder—Methotrexate—esophageal cancer	0.00752	0.00752	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Cisplatin—esophageal cancer	0.00732	0.00732	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Capecitabine—esophageal cancer	0.00718	0.00718	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Capecitabine—esophageal cancer	0.00717	0.00717	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Capecitabine—esophageal cancer	0.00711	0.00711	CcSEcCtD
Ceftaroline fosamil—Angiopathy—Methotrexate—esophageal cancer	0.00696	0.00696	CcSEcCtD
Ceftaroline fosamil—Immune system disorder—Methotrexate—esophageal cancer	0.00693	0.00693	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Cisplatin—esophageal cancer	0.0068	0.0068	CcSEcCtD
Ceftaroline fosamil—Erythema—Methotrexate—esophageal cancer	0.00668	0.00668	CcSEcCtD
Ceftaroline fosamil—Malnutrition—Methotrexate—esophageal cancer	0.00668	0.00668	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00632	0.00632	CcSEcCtD
Ceftaroline fosamil—Vomiting—Cisplatin—esophageal cancer	0.00632	0.00632	CcSEcCtD
Ceftaroline fosamil—Rash—Cisplatin—esophageal cancer	0.00626	0.00626	CcSEcCtD
Ceftaroline fosamil—Pain—Capecitabine—esophageal cancer	0.00626	0.00626	CcSEcCtD
Ceftaroline fosamil—Constipation—Capecitabine—esophageal cancer	0.00626	0.00626	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Cisplatin—esophageal cancer	0.00626	0.00626	CcSEcCtD
Ceftaroline fosamil—Anaemia—Methotrexate—esophageal cancer	0.00617	0.00617	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00599	0.00599	CcSEcCtD
Ceftaroline fosamil—Nausea—Cisplatin—esophageal cancer	0.0059	0.0059	CcSEcCtD
Ceftaroline fosamil—Urticaria—Capecitabine—esophageal cancer	0.00582	0.00582	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Capecitabine—esophageal cancer	0.00579	0.00579	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Capecitabine—esophageal cancer	0.00579	0.00579	CcSEcCtD
Ceftaroline fosamil—Convulsion—Methotrexate—esophageal cancer	0.00579	0.00579	CcSEcCtD
Ceftaroline fosamil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00565	0.00565	CcSEcCtD
Ceftaroline fosamil—Anaphylactic shock—Methotrexate—esophageal cancer	0.00545	0.00545	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Capecitabine—esophageal cancer	0.0054	0.0054	CcSEcCtD
Ceftaroline fosamil—Nervous system disorder—Methotrexate—esophageal cancer	0.00535	0.00535	CcSEcCtD
Ceftaroline fosamil—Thrombocytopenia—Methotrexate—esophageal cancer	0.00534	0.00534	CcSEcCtD
Ceftaroline fosamil—Skin disorder—Methotrexate—esophageal cancer	0.0053	0.0053	CcSEcCtD
Ceftaroline fosamil—Pruritus—Capecitabine—esophageal cancer	0.00518	0.00518	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Capecitabine—esophageal cancer	0.00501	0.00501	CcSEcCtD
Ceftaroline fosamil—Dizziness—Capecitabine—esophageal cancer	0.00484	0.00484	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00471	0.00471	CcSEcCtD
Ceftaroline fosamil—Pain—Methotrexate—esophageal cancer	0.00466	0.00466	CcSEcCtD
Ceftaroline fosamil—Vomiting—Capecitabine—esophageal cancer	0.00466	0.00466	CcSEcCtD
Ceftaroline fosamil—Rash—Capecitabine—esophageal cancer	0.00462	0.00462	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Capecitabine—esophageal cancer	0.00461	0.00461	CcSEcCtD
Ceftaroline fosamil—Headache—Capecitabine—esophageal cancer	0.00459	0.00459	CcSEcCtD
Ceftaroline fosamil—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00446	0.00446	CcSEcCtD
Ceftaroline fosamil—Nausea—Capecitabine—esophageal cancer	0.00435	0.00435	CcSEcCtD
Ceftaroline fosamil—Urticaria—Methotrexate—esophageal cancer	0.00433	0.00433	CcSEcCtD
Ceftaroline fosamil—Abdominal pain—Methotrexate—esophageal cancer	0.00431	0.00431	CcSEcCtD
Ceftaroline fosamil—Body temperature increased—Methotrexate—esophageal cancer	0.00431	0.00431	CcSEcCtD
Ceftaroline fosamil—Hypersensitivity—Methotrexate—esophageal cancer	0.00402	0.00402	CcSEcCtD
Ceftaroline fosamil—Pruritus—Methotrexate—esophageal cancer	0.00386	0.00386	CcSEcCtD
Ceftaroline fosamil—Diarrhoea—Methotrexate—esophageal cancer	0.00373	0.00373	CcSEcCtD
Ceftaroline fosamil—Dizziness—Methotrexate—esophageal cancer	0.00361	0.00361	CcSEcCtD
Ceftaroline fosamil—Vomiting—Methotrexate—esophageal cancer	0.00347	0.00347	CcSEcCtD
Ceftaroline fosamil—Rash—Methotrexate—esophageal cancer	0.00344	0.00344	CcSEcCtD
Ceftaroline fosamil—Dermatitis—Methotrexate—esophageal cancer	0.00343	0.00343	CcSEcCtD
Ceftaroline fosamil—Headache—Methotrexate—esophageal cancer	0.00342	0.00342	CcSEcCtD
Ceftaroline fosamil—Nausea—Methotrexate—esophageal cancer	0.00324	0.00324	CcSEcCtD
